Cargando…

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881), 74.2% reached complete remission (CR) 1 after induction(s) and 59 patients after additiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heinicke, Thomas, Krahl, Rainer, Kahl, Christoph, Cross, Michael, Scholl, Sebastian, Wolf, Hans-Heinrich, Hähling, Detlev, Hegenbart, Ute, Peter, Norma, Schulze, Antje, Florschütz, Axel, Schmidt, Volker, Reifenrath, Kolja, Zojer, Niklas, Junghanss, Christian, Sayer, Herbert G., Maschmeyer, Georg, Späth, Christian, Hochhaus, Andreas, Fischer, Thomas, Al-Ali, Haifa Kathrin, Niederwieser, Dietger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357692/ https://www.ncbi.nlm.nih.gov/pubmed/34232360 http://dx.doi.org/10.1007/s00277-021-04565-1

Ejemplares similares

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
por: Niederwieser, Dietger, et al.
Publicado: (2023)

Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)
por: Krüger, William H., et al.
Publicado: (2021)

Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia
por: Cross, Michael, et al.
Publicado: (2013)

Osho - Insights on sex
por: Nagaraj, Anil Kumar Mysore
Publicado: (2013)

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)
por: Felser, Sabine, et al.
Publicado: (2023)

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)
por: Felser, Sabine, et al.
Publicado: (2023)

Association Between Cancer-Related Fatigue and Falls in Patients With Myeloproliferative Neoplasms: Results of a Multicenter Cross-Sectional Survey From the East German Study Group for Hematology and Oncology (OSHO #97)
por: Felser, Sabine, et al.
Publicado: (2022)

Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2011)

Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO)
por: Jotschke, Sabrina, et al.
Publicado: (2022)

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
por: Heidel, Florian H., et al.
Publicado: (2013)

The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge
por: Niederwieser, Dietger
Publicado: (2021)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world
por: Okamoto, Shinichiro, et al.
Publicado: (2022)

EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression - a case report
por: Krenauer, Alexander, et al.
Publicado: (2010)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Internet-based grief therapy for bereaved individuals after loss due to Haematological cancer: study protocol of a randomized controlled trial
por: Hoffmann, Rahel, et al.
Publicado: (2018)

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
por: Hanoun, Maher, et al.
Publicado: (2022)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
por: Einsele, Hermann, et al.
Publicado: (2003)

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
por: Hell, Saskia, et al.
Publicado: (2022)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
por: McMullin, Mary Frances, et al.
Publicado: (2015)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
por: Brauer, Dominic, et al.
Publicado: (2021)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
por: Finke, Jürgen, et al.
Publicado: (2022)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Autologous Transplantation for Older Adults with AML
por: Mueller, Beatrice U., et al.
Publicado: (2018)

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Uptake of carbon nanodots into human AML cells in comparison to primary hematopoietic cells
por: Nollmann, Cathrin, et al.
Publicado: (2021)

Maximizing the Carrier Mobilities of Metal–Organic Frameworks Comprising Stacked Pentacene Units
por: Zojer, Egbert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6dn1oqbvoik073erkd0jb407nk